Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story

1

The Grail trial randomized 143,000 adults to assess the effectiveness of the Galleri MCED test in reducing advanced cancer stages.
2

The trial failed to meet its primary endpoint of reducing stage 3 and 4 cancers, despite revealing valuable insights into cancer prevalence.
3

Among positive Grail tests, 52% confirmed cancer, indicating a higher positive predictive value compared to other approved screening tests.
4

The trial's paradoxical results showed a decrease in stage 4 cancers but an increase in stage 3 cancers, complicating the interpretation of outcomes.
5

The three-year duration of the trial was shorter than other significant cancer screening studies, potentially affecting the results.

Stat News

1